Arterial and venous cytokine response to cardiopulmonary bypass for low risk CABG and relation to hemodynamics.
During and after cardiopulmonary bypass (CPB), cytokines may affect cardiac performance and the immune response and are therefore of diagnostic and therapeutic interest. We have used EIA/EASIA kits to measure arterial and venous levels of interleukin-1-beta (IL-1-beta), IL-2, IL-2 receptor (IL-2-R), IL-6, tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma in 12 men and 3 women (mean age 59.4 +/- 8.5 years, mean left ventricular ejection fraction 66 +/- 11%, average of 2.5 +/- 0.64 vessels affected by disease) undergoing elective coronary artery bypass grafting (CABG). On average each patient received 3 +/- 0.85 bypass grafts and required a postoperative maximum dopamine-dose of 3.8 micrograms/kg per min. Mean CPB and operation times were 60 +/- 21 min, and 132 +/- 16 min, respectively. During CPB, the venous levels of IL-2 temporarily decreased from 234 to 0 (p < 0.05) pg/ml and arterial and venous levels of IL-2-R temporarily decreased from 28 to 16, and 36 to 18 pM (p < 0.05), respectively. After termination of CPB, there was an increase in the arterial and venous levels of IL-6 from below 3 to 253 and 277 pg/ml (p < 0.05) and TNF-alpha from 1.1 to 5.7 and 0.7 to 4.0 pg/ml, respectively (p < 0.05). Tumor necrosis factor-alpha-increases peaked 30 min, and IL-6 increases peaked 4 h after termination of CPB. Twenty-four hours after the end of CPB, IL-6 showed a tendency to return to baseline, but still remained significantly elevated.(ABSTRACT TRUNCATED AT 250 WORDS)
Deng
M C
MC
Department of Thoracic and Cardiovascular Surgery, Westfalian Wilhelms-University, Münster, Germany.
Wiedner
M
M
Erren
M
M
Möllhoff
T
T
Assmann
G
G
Scheld
H H
HH
D000293:Adolescent; D000328:Adult; D000368:Aged; D001158:Arteries; D002315:Cardiopulmonary Bypass; D001026:Coronary Artery Bypass; D003331:Coronary Vessels; D017558:Elective Surgical Procedures; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006439:Hemodynamics / Q000502:physiology*; D006801:Humans; D007371:Interferon-gamma / Q000097:blood*; D007375:Interleukin-1 / Q000097:blood*; D053583:Interleukin-1beta; D007376:Interleukin-2 / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D011182:Postoperative Care; D011300:Preoperative Care; D011669:Pulmonary Wedge Pressure / Q000502:physiology; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D012016:Reference Values; D012307:Risk Factors; D012995:Solubility; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014680:Veins
D007375:Interleukin-1; D053583:Interleukin-1beta; D007376:Interleukin-2; D015850:Interleukin-6; D010446:Peptide Fragments; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha; C052994:interleukin-1beta (163-171); D007371:Interferon-gamma